Efficacy of intradermal immunotherapy to pet (cats and dogs) allergies.

Efficacy of intradermal immunotherapy using maximum intradermally tolerated dose to pet (cats and dogs) allergies. - MITD-IDIT PETALS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053784

Enrollment

Registered

2024-03-10

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pet (dogs and cats) allergies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Individuals who meet any of the following: positive specific IgE antibody values, positive skin prick test which shows wheal 4mm or more compared to the negative control, positive intradermal test which shows wheal diameter expansion of 2mm or more. 2.Those for whom conventional medication, such as oral anti-allergic agents, topical drugs, and inhalants, is insufficient.

Exclusion criteria

Exclusion criteria: 1.individuals currently using beta-blockers, calcium channel blockers, antidepressants, other psychiatric drugs, anti-IgE antibodies, biologics, cytokine receptor antibodies, immunosuppressants, or oral steroids as treatment. 2.Individuals who are pregnant or may be pregnant. 3.Individuals undergoing treatment for or suspected of having malignant neoplasms. 4.Individuals with a history of fatal anaphylaxis or angioedema.

Design outcomes

Primary

Measure	Time frame
Change in severity of each symptom by pet before and after treatment using visual analogue scale (VAS).	—

Countries

Japan

Contacts

Public Contactkyoko nishikage

Yokohama-Nishikage clinic, kids and allergies medical department

kyoko@yokohama-nishikage.clinic0453235115

Outcome results